Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study

Inclusion Criteria:

• Patient over 18 years of age

• Patients with a diagnosis of RA according to ACR/EULAR 2010 criteria

• Remission according to DAS28<=2.6 for at least 6 months

• Patient treated with ADA for at least 6 months. The patient is treated according toone of the following two strategies:

• ADA 40 mg every two weeks (= every 14 days) according to the standard regimen

• or ADA 40 mg every 3 weeks (= every 21 days)

• A negative highly sensitive pregnancy test for women of Childbearing Potential*

• Affiliated person or beneficiary of a social security scheme

• Informed consent signed by the patient after information

Exclusion Criteria:

• Incapacity or refusal to understand and / or sign informed consent to participate inthe study.

• Existing pregnancy, lactation, or intended pregnancy within the next 15 months

• Fibromyalgia associated to RA

• Any dose of prednisone for RA treatment 6 months before inclusion

• Patient deprived of liberty or patient under guardianship or curator ship.